QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
QIAGEN received FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, marking its entry into the U.S. bloodstream infection testing market. The panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour, supporting faster treatment decisions.
Key figures
- Pathogen targets
- 20
- Result time hours
- 1
- Resistance markers
- 10
- Countries available
- more than 100
- Cumulative placements
- more than 5,200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.